- Compiles the most recent and comprehensive findings in pharmacological targets
- Highlights the role of extrinsic and intrinsic factors involved in disease development
- Written by leading researchers in the field of Irritable Bowel Syndrome to address research challenges in the field
- Includes bonus information on symptom recognition and diagnosis
1. Introduction to irritable bowel syndrome: General overview and epidemiology 2. Pathogenesis of irritable bowel syndrome 3. Irritable bowel syndrome and the brain-gut connection 4. The control of the intestinal epithelium integrity in irritable bowel syndrome patients 5. Irritable bowel syndrome and gut microbiota 6. Gender-related differences and significance of gonadal hormones in irritable bowel syndrome 7. Genetic aspect (with SNPs) of irritable bowel syndrome 8. Clinical diagnosis of irritable bowel syndrome 9. Biomarkers of irritable bowel syndrome 10. Irritable bowel syndrome: Current therapies and future perspectives 11. Pain in irritable bowel syndrome 12. Non-pharmacological approach in irritable bowel syndrome therapy 13. Diet in irritable bowel syndrome 14. Correlation of irritable bowel syndrome with psychiatric disorders 15. Preclinical models of irritable bowel syndrome
Jakub Fichna is a pharmacist, pharmacologist and gastroenterologist, appointed Head of Department of Biochemistry at the Medical University of Lodz, Poland. He has co-authored more than 250 peer-reviewed publications and 8 book chapters, focusing principally on novel pharmacological targets for the treatment of functional and inflammatory diseases of the gastrointestinal tract. In his studies, Dr. Fichna employs in vitro, ex vivo, and in vivo models of gastrointestinal diseases. His numerous collaborations with university clinics and private healthcare units allow him to conduct clinical experiments and process patients' data for his research. Dr. Fichna is a recipient of the UEG Rising Star 2016 Award and a member of the French Academie Nationale de Pharmacie.